Madopar Depot (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted to dopamine, replenishing deficient central neurotransmission. Benserazide inhibits peripheral aromatic L‑amino acid decarboxylase, preventing levodopa breakdown outside the brain, thereby increasing the amount that reaches the central nervous system and reducing peripheral side effects.

The exact dose of Madopar Depot is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Typically, treatment starts with a low dose that is gradually titrated to achieve optimal symptom control while minimizing adverse effects.

The safety of Madopar Depot during pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Madopar Depot, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Madopar Depot provides a prolonged, steady release of levodopa, which can reduce dosing frequency and smooth plasma concentration fluctuations compared with immediate‑release tablets. This may lead to fewer motor “off” periods and a lower incidence of peak‑dose dyskinesia, though individual response varies.

Madopar Depot tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Madopar Depot is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing relative to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include the development of dyskinesia, severe orthostatic hypotension, psychiatric disturbances such as hallucinations, and rare but life‑threatening reactions like neuroleptic malignant‑like syndrome or anaphylaxis. Prompt medical attention is required if any of these occur.

Madopar Depot is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients. It should also be avoided in individuals taking non‑selective MAO‑B inhibitors, or in patients with severe cardiovascular disease where orthostatic hypotension could be hazardous.